

Preferred

ESTROGEN MODIFIERS PA SUMMARY

Non-Preferred

Preferred Estrogens:	Non-Preferred Estrogen/SERM Combinations:
Cenestin (estrogens, conjugated synthetic A)	Duavee (conjugated estrogens/bazedoxifene)
Enjuvia (estrogens, conjugated synthetic B)	
Estradiol generic	
Estropipate generic	
Menest (esterified estrogens)	Non-Preferred Estrogen/Progestin Combinations:
Premarin (estrogens, conjugated)	Estradiol/norethindrone generic
Preferred Estrogen/Progestin Combinations:	
Activella (estradiol/norethindrone)	
Angeliq (drospirenone/estradiol)	
Femhrt (norethindrone/ethinyl estradiol)	
Jinteli generic (norethindrone/ethinyl estradiol)	
Prefest (estradiol/norgestimate)	
Premphase (conjugated estrogens/medroxyprogesterone)	
Prempro (conjugated estrogens/medroxyprogesterone)	
	Non-Preferred Topical Estrogens
Preferred Selective Estrogen Receptor Modulator	Divigel (estradiol topical gel)
(SERMs):	Elestrin (estradiol topical gel)
Raloxifene generic	Estradiol transdermal patch (generic Climara)
	Estrasorb (estradiol topical emulsion)
Preferred Topical Estrogens	Estrogel (estradiol topical gel)
Alora (estradiol transdermal patch)	Evamist (estradiol topical spray solution)
Climara (estradiol transdermal patch)	Minivelle (estradiol transdermal patch)
Climara Pro (estradiol/levonorgestrel transdermal patch)	
Combipatch (estradiol/norethindrone transdermal patch)	
Estraderm (estradiol transdermal patch)	
Menostar (estradiol transdermal patch)	
Vivelle (estradiol transdermal patch)	
Vivelle-Dot (estradiol transdermal patch)	

LENGTH OF AUTHORIZATION: 1 Year

PA CRITERIA:

For Duavee

- ❖ Approvable for the prevention of postmenopausal osteoporosis in women with an intact uterus who have experienced ineffectiveness, allergies, contraindications, drug-drug interactions, or a history of intolerable side effects to Evista AND the preferred bisphosphonate, alendronate generic (Fosamax).
- Approvable for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with an intact uterus who have experienced ineffectiveness, allergies, contraindications, drug-drug interactions, or a history of intolerable side effects to at least two preferred estrogen or estrogen/progestin products.

For Estradiol/Norethindrone Generic

❖ Physician must submit a written letter of medical necessity stating the reasons brand Activella is not appropriate for the member.



For Divigel, Elestrin, Estrasorb, Estrogel, Evamist and Minivelle

❖ Approvable for members who have experienced ineffectiveness or a history of intolerable side effects to two preferred estradiol transdermal patches.

For Estradiol Transdermal Patch (generic Climara)

❖ Physician must submit a written letter of medical necessity stating the reasons brand Climara is not appropriate for the member.

EXCEPTIONS:

- * Exceptions to these conditions of coverage are considered through the prior authorization process.
- ❖ The Prior Authorization process may be initiated by calling Catamaran at 1-866-525-5827.

PA and APPEAL PROCESS:

❖ For online access to the PA process, please go to www.dch.georgia.gov/prior-authorization-process-and-criteria and click on Prior Authorization (PA) Request Process Guide.

QUANTITY LEVEL LIMITATIONS:

For online access to the current Quantity Level Limits (QLL), please go to www.mmis.georgia.gov/portal, highlight Provider Information and click on Provider Manuals. Scroll to the page with Pharmacy Services and select that manual.